MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...

Discover the top 3 undervalued Automobile Components stocks for Friday, December 26 based on AAII’s Stock Grades.

Caroline Banton has 6+ years of experience as a writer of business and finance articles. She also writes biographies for Story Terrace. David Kindness is a Certified Public Accountant (CPA) and an ...

Unveiling the coupling effect of sp 2 domain size and local active sites in switching the selectivity of nanocarbon catalysts toward the oxygen electro-reduction Carbon-mediated oxygen reduction is ...

MSD's booth is seen during an expo in Shanghai in November. [PHOTO/CHINA DAILY] With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to ...

Dec. 21, 2025 Superconductors promise loss-free electricity, but most only work at extreme cold. Hydrogen-rich materials changed that—yet their inner workings remained hidden because they only exist ...